Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Sereti on the Next Steps for NOV202 Plus Olaparib in BRCA1/2-Mutated Prostate Cancer

July 12th 2021

Evangelia Sereti, MSc, PhD, discusses the next steps with the combination of NOV202 and olaparib in BRCA1/2-mutated prostate cancer.

Darolutamide Demonstrates Favorable Tolerability in Nonmetastatic CRPC

July 12th 2021

Treatment with darolutamide induced a low cumulative incidence of hormone treatment–related adverse effects that was comparable to treatment with placebo in patients with nonmetastatic castration-resistant prostate cancer, according to findings from a safety analysis of the phase 3 ARAMIS trial.

Abiraterone/Prednisone Combo Linked With Improvements in Fatigue and QoL, But Worsening Metabolic Changes in mCRPC

July 12th 2021

Abiraterone acetate plus prednisone should be considered as the first treatment choice for patients with newly diagnosed metastatic castration-resistant prostate cancer if fatigue is a concern.

Darolutamide Crossover Leads to High PSA Response in Nonmetastatic CRPC

July 12th 2021

Eighty-five percent of patients with nonmetastatic castration-resistant prostate cancer who crossed over from placebo to darolutamide in the phase 3 ARAMIS trial experienced a maximum prostate-specific antigen decline of at least 50% at any time of crossover.

Apalutamide Plus ADT Improves Survival Regardless of Disease Volume in mCSPC

July 12th 2021

Investigators demonstrated that the benefit of androgen deprivation therapy was extended with the addition of apalutamide for patients with metastatic castration-sensitive prostate cancer regardless of disease volume.

Neoadjuvant Apalutamide Does Not Interfere With Robotic Prostatectomy

July 12th 2021

Intense androgen receptor inhibition with neoadjuvant apalutamide did not complicate robotic prostatectomy surgical outcomes.

Patients With Urological Cancer and COVID-19 Undergoing Elective Surgery at Higher Risk for Mortality

July 10th 2021

Patients with a urological cancer who were also infected with COVID-19 and undergoing elective surgery for their disease, were found to have a significantly higher likelihood of experiencing respiratory complications and mortality than those without the virus.

Dr. Sereti on the Preclinical Efficacy of NOV202 Plus Olaparib in BRCA1/2-Mutated Prostate Cancer

July 10th 2021

Evangelia Sereti, MSc, PhD, discusses the preclinical efficacy of NOV202 plus olaparib in BRCA1/2-mutated prostate cancer cells.

Dr. Wagaskar on the Rationale to Evaluate the Obesity Paradox in Prostate Cancer

July 10th 2021

Vinayak G. Wagaskar, MBBS, discusses the rationale to evaluate the relationship between obesity paradigm and outcomes in prostate cancer.

Dr. Tagawa on Tumor Targeting With Radionuclides in Prostate Cancer

July 8th 2021

Scott T. Tagawa, MD, MS, FACP, discusses tumor targeting with radionuclides in prostate cancer.

Adjuvant Radiation Therapy Could Yield Reduction in All-Cause Mortality in High-Risk Prostate Cancer

July 6th 2021

Men with positive pelvic lymph nodes or a prostatectomy Gleason score of 8 to 10 with disease extending beyond the prostate should be considered for treatment with adjuvant radiation therapy.

Rapid Readouts: Final Analysis of Phase 3 TITAN Trial

July 6th 2021

Scott T. Tagawa, MD, MS, FACP, reports on data presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting regarding health-related quality of life (HRQoL) and patient-reported outcomes (PROs) at the final analysis of TITAN, a phase 3 study evaluating apalutamide versus placebo in patients with metastatic castration-sensitive prostate cancer (mCSPC) who were receiving androgen deprivation therapy (ADT).

Mount Sinai Welcomes Robotic Prostate Surgery Pioneer Mani Menon, MD

June 30th 2021

Robotic prostate surgery pioneer Mani Menon, MD, is joining Mount Sinai and will serve as Chief of Strategy and Innovation in the Department of Urology for the Mount Sinai Health System.

Rapid Readouts: Extended Follow-up From the Phase 3 ARAMIS trial

June 30th 2021

Neal Shore, MD, presents data on the tolerability of and responses to darolutamide (DARO) as seen in the extended follow-up of the phase 3 ARAMIS trial of DARO treatment in men with high-risk, nonmetastatic, castration-resistant prostate cancer. The results were reported at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.

Rapid Readouts: Treatment Preference Results From the Phase 2 ODENZA Trial

June 30th 2021

Neal Shore, MD, presents data on treatment preferences from the phase 2 ODENZA trial of darolutamide and enzalutamide in men with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer. The results were reported at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.

VERU-111 Shows Potential for Safe, Long-Term Treatment in Metastatic CRPC

June 25th 2021

Eric Klein, MD, discusses the promise of VERU-111 in patients with metastatic CRPC and other research efforts that are generating excitement in the paradigm.

Dr. Shore on the Design of the ARAMIS Trial With Darolutamide in nmCRPC

June 24th 2021

Neal D. Shore, MD, FACS, discusses the design of the phase 3 ARAMIS trial in nonmetastatic castration-resistant prostate cancer.

Sequential 177Lu-PSMA-617 Plus Docetaxel Under Examination in Metastatic Hormone-Naïve Prostate Cancer

June 22nd 2021

Arun Azad, MBBS, PhD, FRACP, discusses the rationale that inspired the launch of the UpFrontPSMA trial, and highlights past and future research directions with 177Lu-PSMA-617 in the treatment of patients with prostate cancer.

Dr. Juárez Soto on the Efficacy of Apalutamide Plus ADT in mHSPC

June 21st 2021

Álvaro Juárez Soto, MD, discusses the efficacy of apalutamide plus androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer.

Dr. Klein on the Rationale to Evaluate VERU-111 in mCRPC

June 21st 2021

Eric Klein, MD, discusses the rationale to evaluate VERU-111 in metastatic castration-resistant prostate cancer.